Mod­er­na inks deal for over­seas Covid-19 vac­cine fin­ish­ing work as Eu­ro­pean ap­proval hangs in bal­ance

De­spite a lack of for­mal ap­proval from the Eu­ro­pean Med­i­cines Agency, Mod­er­na is mov­ing to nail down pro­duc­tion ca­pac­i­ty for the dos­es of its mR­NA-based Covid-19 vac­cine that will be jabbed in­to arms out­side of the U.S.

Just be­fore the new year, Mod­er­na inked a deal with Re­ci­pharm, the Swedish CD­MO, for for­mu­lat­ing and fill-fin­ish work on an undis­closed por­tion of Mod­er­na’s vac­cine sup­ply out­side of the US at Re­ci­pharm’s drug prod­uct man­u­fac­tur­ing fa­cil­i­ty lo­cat­ed in France.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER